Meanwhile, the BSE Sensex was up 36.85 points or 0.19% at 19,943.26.
On BSE, 57,000 shares were traded in the counter as against average daily volume of 1.29 lakh shares in the past one quarter.
The stock hit a high of Rs 2,810 and a low of Rs 2,778.35 so far during the day. The stock had hit a 52-week high of Rs 2,990 on 22 February 2012. The stock had hit a 52-week low of Rs 2,101.65 on 26 July 2012.
The stock had outperformed the market over the past one month till 14 January 2013, surging 23.27% compared with the Sensex's 3.05% rise. The scrip had also outperformed the market in past one quarter, jumping 17.18% as against Sensex's 6.59% surge.
The large-cap IT company has equity capital of Rs 287.12 crore. Face value per share is Rs 5.
Shares of Infosys had rallied 20.98% in two trading sessions to settle at Rs 2,807.25 on Monday, 14 January 2013, from a recent low of Rs 2,320.35 on 10 January 2013, after the company's CEO and Managing Director S. D. Shibulal at the time of announcement of the company's Q3 December 2012 results before trading hours on Friday, 11 January 2013, that the management continues to gain confidence from a strong pipeline of large deals. Infosys won 8 large outsourcing deals amounting to $731 million of total contract value in Q3 December 2012.
Infosys has partnered with NovaSom, Inc., the leader in home testing for obstructive sleep apnea (OSA), to significantly improve the efficiency of administering and analyzing results of home tests. Infosys has designed an innovative cloud-based user portal, Meditrack, on Salesforce.com to broaden the reach and efficiency of NovaSom's diagnostic solution suite. The new portal provides physicians with a single, easy-to-use interface that speeds up the order-to-delivery of devices, processing of diagnostic data and management of insurance claims, Infosys and NovaSom said in a joint statement on Monday, 14 January 2013.
Commenting on the development, Dheeshjith V.G., Senior Vice President and Global Head, Life Sciences at Infosys said, "Patients with OSA are at an increased risk of other chronic diseases. The innovative solution that we developed for NovaSom is helping OSA patients receive faster and better medical care. Leveraging our deep medical technology domain knowledge and harnessing the latest technical advancements has allowed us to enable NovaSom to facilitate rapid diagnostic and therapy cycles".
Richard Hassett, MD, Chief Executive Officer, NovaSom said, "A quicker OSA diagnosis is critical to helping sufferers get the therapy they need sooner, and we are achieving that goal wit the help of Infosys. The customized MediTrack portal enables us to complete tests quickly and accurately. NovaSom's cloud-based infrastructure allows us to partner with providers to improve access to care, reduce cost and address this undiagnosed epidemic".
NovaSom, Inc. is the market leader in obstructive sleep apnea home testing, with the AccuSom Home Sleep Test, the first and only FDA-cleared wireless HST. NovaSom's home sleep tests are currently covered for more than 165 million Americans through partnerships with major health insurers.
Infosys' consolidated net profit as per International Financial Reporting Standards (IFRS) remained unchanged on sequential basis at Rs 2369 crore in Q3 December 2012. Revenue rose 5.7% to Rs 10424 crore in Q3 December 2012 over Q2 September 2012. Revenues excluding Lodestone rose 3.6% to Rs 10210 crore in Q3 December 2012 over Q2 September 2012. Infosys completed the acquisition of Lodestone Holding AG, a leading management consultancy based in Switzerland, in Q3 December 2012.
Due to addition of revenue from Lodestone, Infosys has raised revenue guidance for the year ending 31 March 2013 (FY 2013). With expected revenue of $104 million from Lodestone for FY 2013, Infosys has forecast total revenue at $7.45 billion for the company for FY 2013. At the time of announcement of Q2 September 2012 results on 12 October 2012, Infosys had forecast revenue of $7.343 billion for FY 2013 when Lodestone acquisition was yet to be completed. The company has retained guidance for earnings per American depository receipt (EPADS) for FY 2013 at a minimum $2.97.
In rupee terms, Infosys now expects revenue of Rs 40746 crore for FY 2013 which includes projected revenue of Rs 568 crore from Lodestone. At the time of announcement of Q2 September 2012 results on 12 October 2012, Infosys had forecast revenue of Rs 39582 for FY 2013 when Lodestone acquisition was yet to be completed. The company has raised the guidance for earnings per share for FY 2013 to Rs 162.80 from its October guidance of EPS of Rs 160.61.
Infosys partners with global enterprises to drive their innovation-led growth. As a leading provider of next-generation consulting, technology and outsourcing solutions, Infosys helps clients in more than 30 countries realize their goals.
Powered by Capital Market - Live News
